JP5807788B2 - ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用 - Google Patents

ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用 Download PDF

Info

Publication number
JP5807788B2
JP5807788B2 JP2012540503A JP2012540503A JP5807788B2 JP 5807788 B2 JP5807788 B2 JP 5807788B2 JP 2012540503 A JP2012540503 A JP 2012540503A JP 2012540503 A JP2012540503 A JP 2012540503A JP 5807788 B2 JP5807788 B2 JP 5807788B2
Authority
JP
Japan
Prior art keywords
cancer
mth
treatment
virus
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012540503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511975A5 (OSRAM
JP2013511975A (ja
Inventor
サタリー，クリスティン，エム．，エムディー．
サタリー，ラズロ，ケー．，エムディー．
Original Assignee
ユナイテッド キャンサー リサーチ インスティトゥート
ユナイテッド キャンサー リサーチ インスティトゥート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド キャンサー リサーチ インスティトゥート, ユナイテッド キャンサー リサーチ インスティトゥート filed Critical ユナイテッド キャンサー リサーチ インスティトゥート
Publication of JP2013511975A publication Critical patent/JP2013511975A/ja
Publication of JP2013511975A5 publication Critical patent/JP2013511975A5/ja
Application granted granted Critical
Publication of JP5807788B2 publication Critical patent/JP5807788B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
JP2012540503A 2009-11-30 2010-08-13 ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用 Expired - Fee Related JP5807788B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28315409P 2009-11-30 2009-11-30
EP09075536A EP2327764B1 (en) 2009-11-30 2009-11-30 New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
EP09075536.4 2009-11-30
US61/283,154 2009-11-30
PCT/IB2010/002227 WO2011064630A1 (en) 2009-11-30 2010-08-13 New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Publications (3)

Publication Number Publication Date
JP2013511975A JP2013511975A (ja) 2013-04-11
JP2013511975A5 JP2013511975A5 (OSRAM) 2013-10-03
JP5807788B2 true JP5807788B2 (ja) 2015-11-10

Family

ID=41581942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540503A Expired - Fee Related JP5807788B2 (ja) 2009-11-30 2010-08-13 ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用

Country Status (11)

Country Link
US (2) US8377450B2 (OSRAM)
EP (2) EP2327764B1 (OSRAM)
JP (1) JP5807788B2 (OSRAM)
KR (1) KR20120106741A (OSRAM)
CN (1) CN102803477B (OSRAM)
AT (1) ATE539148T1 (OSRAM)
CA (1) CA2782189C (OSRAM)
DK (1) DK2327764T3 (OSRAM)
ES (1) ES2380289T3 (OSRAM)
IL (1) IL207623A (OSRAM)
WO (1) WO2011064630A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380289T3 (es) * 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
KR101636683B1 (ko) * 2013-08-28 2016-07-07 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄｍ
KR101653401B1 (ko) * 2013-08-28 2016-09-12 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄ
EP3957644B1 (en) * 2014-11-07 2024-08-07 Case Western Reserve University Cancer immunotherapy using virus particles
RU2644676C1 (ru) * 2016-10-18 2018-02-13 Общество с ограниченной ответственностью "Витагор" (ООО "ВИТАГОР") Штамм вируса болезни Ньюкасла NDVH-2 для изучения возможности разработки на его основе вирусного онколитического препарата
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
WO2020043835A1 (en) * 2018-08-31 2020-03-05 Thaller, Arno Novel recombinant newcastle disease virus
CN113913553B (zh) * 2021-10-15 2024-08-27 广西壮族自治区兽医研究所 基因ⅻ型新城疫病毒荧光定量rt-pcr检测试剂盒及其引物对

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
HU203983B (en) 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ATE229344T1 (de) 1992-03-24 2002-12-15 United Cancer Res Inst Impfstoff enthaltend lebendes virus
FR2701580B1 (fr) 1993-02-10 1995-03-24 Bull Sa Procédé d'administration d'applications avec des protocoles standards.
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
JPH08116976A (ja) 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
AU4606000A (en) 1999-06-10 2001-01-02 Agricultural Research Council Vaccine for newcastle disease virus
CA2414396A1 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agricul Ture Production of vaccines using transgenic plants
EP1297121B1 (en) 2000-06-26 2005-05-04 Wellstat Biologics Corporation Purging of cells using viruses
ATE352557T1 (de) 2000-11-02 2007-02-15 Intervet Int Bv Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
IL145397A0 (en) 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
EP2266601A1 (en) 2002-06-21 2010-12-29 Wellstat Biologics Corporation Administration of therapeutic viruses
EP1542753B1 (en) * 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
JP2006510741A (ja) 2002-11-05 2006-03-30 ウェルスタット バイオロジックス コーポレイション 治療用ウイルスによるカルチノイド新生物の処置
MXPA05010173A (es) 2003-03-24 2005-11-08 Wellstat Biologics Corp Metodo de desensibilizacion con virus anti-cancer.
MXPA05010172A (es) 2003-03-24 2005-11-08 Wellstat Biologics Corp Administracion del virus de la enfermedad de newclastle.
WO2005051433A1 (en) 2003-11-25 2005-06-09 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
US20060018836A1 (en) 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain having a p53 independent oncolytic effect
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2091972B1 (en) 2006-11-27 2016-01-13 Schirrmacher, Dr., Volker Multi-modal cancer therapy using viral hitch-hiking
US20100178684A1 (en) * 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
CN101205544B (zh) * 2007-08-07 2010-12-08 中国人民解放军第四军医大学 肿瘤靶向性重组新城疫病毒及其构建方法
ES2380289T3 (es) * 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer

Also Published As

Publication number Publication date
CN102803477B (zh) 2014-12-10
WO2011064630A1 (en) 2011-06-03
ATE539148T1 (de) 2012-01-15
US20110129446A1 (en) 2011-06-02
EP2507366A1 (en) 2012-10-10
US20140030229A1 (en) 2014-01-30
IL207623A0 (en) 2011-03-31
HK1175495A1 (en) 2013-07-05
CN102803477A (zh) 2012-11-28
ES2380289T3 (es) 2012-05-10
US8377450B2 (en) 2013-02-19
KR20120106741A (ko) 2012-09-26
IL207623A (en) 2014-04-30
CA2782189A1 (en) 2011-06-03
JP2013511975A (ja) 2013-04-11
DK2327764T3 (da) 2012-04-02
WO2011064630A8 (en) 2012-05-24
CA2782189C (en) 2018-07-10
EP2327764B1 (en) 2011-12-28
EP2327764A1 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
JP5807788B2 (ja) ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用
JP4338781B2 (ja) ウイルスを用いる癌の処置および検出方法
US20100172877A1 (en) Compositions and methods of use of an oncolytic vesicular stomatitis virus
JP2001519175A (ja) ウイルスを用いた新生物の処置
WO2013112690A1 (en) Piv5 as oncolytic agent
JP2011510638A (ja) トリサイトカインをコードする弱毒化腫瘍退縮パラミクソウイルス
Zulkifli et al. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
EP3747997A1 (en) Pseudorabies virus for treating tumors
CN117085047A (zh) 优化的溶瘤病毒及其用途
JP5782511B2 (ja) がん幹細胞（ｃｓｃ）を除去するためのパルボウイルスの使用
BR112020009907A2 (pt) composições e métodos para melhorar produção, crescimento, disseminação, ou eficácia oncolítica e imunoterapêutica de vírus sensíveis a interferon
WO2019015601A1 (zh) 一种用于治疗肿瘤的病毒
Künzi et al. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo
JP5897700B2 (ja) 腫瘍崩壊におけるトリメタニューモウイルス
US9526779B2 (en) Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus
WO2019201192A1 (zh) 一种用于治疗肿瘤的柯萨奇b组病毒
WO2022033469A1 (zh) 重组溶瘤病毒及其构建方法和用途
WO2019174610A1 (zh) 一种溶瘤病毒、合成dna序列及其应用
HK1175495B (en) New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US20240245739A1 (en) Oncolytic virus based cancer therapy
Jäkel In vivo characterization of a pseudotyped vesicular stomatitis virus for the treatment of Hepatocellular carcinoma
Addisu Demeke et al. Current advancements on the significance of oncolytic viruses in the treatment of tumor cells.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150826

R150 Certificate of patent or registration of utility model

Ref document number: 5807788

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees